PFKFB3 and cancer: Since ECs are very sensitive to even small changes in glycolysis levels and, in fact, more responsive to PFKFB3 blockade than various cancer cell lines in vitro [83], a clinical trial with another design using lower doses of the PFKFB3 blocker will be required to test whether PFKFB3 blockade can impair metastasis, while improving standard care therapy by promoting tumor vessel normalization.